Arvinas is betting its future on a small handful of experimental medicines that aim to remove harmful proteins, which could pay off if the first of these drugs reaches patients. But with key programs scaled back and heavy dependence on big-partner deals, delays, pricing pushback, or stronger rivals could keep the business under pressure longer than many expect.Read more
Arvinas aims to turn hard-to-treat diseases into drug targets by getting the body to break down harmful proteins, and a few upcoming trial results could open much bigger markets than many expect. But the story hinges on only a handful of drug candidates and key partners, so a setback in trials, regulation, or competition could quickly change the outlook.Read more
Key Takeaways Advancements in targeted therapies and partnerships position Arvinas to capitalize on precision medicine trends and diversify future revenue streams. Streamlined operations and supportive industry momentum enhance prospects for improved margins and faster approval timelines.Read more
Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company develops proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins. It is also developing clinical development programs , including ARV-102, a leucine-rich repeat kinase 2 (LRRK2) protein for the treatment of neurodegenerative diseases, such as Parkinson's disease and progressive supranuclear palsy; ARV-806, a Kirsten rat sarcoma, G12D protein for the treatment of cancers with the G12D mutation, comprising pancreatic, colorectal, and non-small cell lung cancer; ARV-393, a B-cell lymphoma 6 protein for the treatment of relapsed/refractory non-Hodgkin lymphoma (NHL); ARV-027, a polyglutamine-expanded androgen receptor in skeletal muscle; and vepdegestrant, an estrogen receptor for the treatment of locally advanced or metastatic ER+/HER2- breast cancer. In addition, the company develops Bavdegalutamide (ARV-110) and Luxdegalutamide (ARV-766), investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer. It has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.
